Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis

J Clin Pathol. 2018 Aug;71(8):752-753. doi: 10.1136/jclinpath-2018-205160. Epub 2018 Apr 27.

Authors

Lucile Regard^{1

2}, Clémence Martin^{1

2}, Leila Zemoura³, Virginie Geolier¹, Edouard Sage⁴, Pierre-Régis Burgel^{1

2}

Affiliations

¹ Paris Descartes University, Sorbonne Paris Cité, Paris, France.
² Pulmonary Department and Adult Cystic Fibrosis Center, Cochin Hospital, Paris, France.
³ Pathology Department, Foch Hospital, Suresnes, France.
⁴ Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.

PMID: 29703760
DOI: 10.1136/jclinpath-2018-205160

No abstract available

Keywords: airways disease; lymphocytes; monoclonal antibody; transplantation.

Publication types

Letter

MeSH terms

Adult
Cystic Fibrosis / drug therapy
Cystic Fibrosis / pathology*
Female
Humans
Immunologic Factors / therapeutic use*
Lung / drug effects
Lung / pathology*
Rituximab / therapeutic use*
Tertiary Lymphoid Structures / pathology*

Substances

Immunologic Factors
Rituximab